Elsevier

Gene

Volume 762, 15 December 2020, 145019
Gene

Research paper
Associations between peroxisome proliferator-activated receptor γ (PPAR-γ) polymorphisms and serum lipids: Two cross-sectional studies of community-dwelling adults

https://doi.org/10.1016/j.gene.2020.145019Get rights and content

Highlights

  • We conducted two cross-sectional studies of community-dwelling adults.

  • We examined the association of PPAR-γ polymorphisms with serum lipids.

  • Two polymorphisms were related to a lower prevalence of dyslipidemia and/or high LDL-C.

  • Similar reductions in prevalence were found in the second survey.

Abstract

Dyslipidemia is a well-established risk factor for cardiovascular disease. Experimental studies have reported that peroxisome proliferator-activated receptor γ (PPAR-γ) regulates adipocyte differentiation, lipid storage, and glucose metabolism. Therefore, we examined the associations between PPAR-γ polymorphisms (rs1801282, rs3856806, rs12497191, rs1151999, and rs1152003) and serum lipids in two cross-sectional studies. In the Shizuoka area of the Japan Multi-Institutional Collaborative Cohort Study, we examined 4,952 participants (3,356 men and 1,596 women) in a baseline survey and 2,245 participants (1,550 men and 695 women) in a second survey 5 years later. Outcome measures were the prevalence of dyslipidemia (low-density lipoprotein-cholesterol [LDL-C] ≥ 140 mg/dl, high-density lipoprotein-cholesterol < 40 mg/dl, triglycerides ≥ 150 mg/dl, and/or use of cholesterol-lowering drugs) and the prevalence of high LDL-C (LDL-C ≥ 140 mg/dl and/or use of cholesterol-lowering drugs). Multivariate odds ratios (ORs) were estimated by using unconditional logistic regression models. A total of 2,114 and 1,431 individuals (42.7% and 28.9%) had dyslipidemia and high LDL-C in the baseline survey, respectively, as did 933 and 716 (41.6% and 31.9%), respectively, in the second survey. In the baseline study, compared with major allele homozygotes, minor allele homozygotes of rs3856806 and rs12497191 had a 42% (OR, 0.58; 95% confidence interval (CI), 0.39–0.85) and 23% (OR, 0.77; 95% CI, 0.60–0.99) lower risk of dyslipidemia, respectively, after adjustment for potential confounding factors. In addition, minor allele homozygotes of rs3856806 had a 45% (OR, 0.55; 95% CI, 0.35–0.86) lower risk of high LDL-C. Similar risk reductions were found in the second survey. In conclusion, rs3856806 and rs12497191 polymorphisms may be related to a lower risk of dyslipidemia and high LDL-C.

Introduction

Cardiovascular disease (ischemic heart disease and stroke) is one of the leading causes of mortality and disability in the world (GBD 2015 Mortality and Causes of Death Collaborators, 2015, GBD 2017 DALYs and HALE Collaborators, 2018). Dyslipidemia is a well-established risk factor for cardiovascular disease (Baigent et al., 2010, Boekholdt et al., 2013, Sarwar et al., 2007); specifically, 1.0 mmol/l (38.67 mg/dl) reduction in low-density lipoprotein-cholesterol (LDL-C) is associated with a 22% risk reduction of cardiovascular disease at 1 year (Baigent et al., 2010). In Japan, 22.0% of men and 23.3% of women aged 20 years or older had a serum LDL-C of 140 mg/dl or higher, and 13.0% of men and 18.0% of women were prescribed cholesterol-lowering drugs according to the National Health and Nutrition Survey in Japan in 2018 Ministry of Health, Labour and Welfare. 2018). Therefore, effective strategies are needed for prevention and treatment of dyslipidemia to reduce mortality and disability caused by cardiovascular disease.

Dyslipidemia results from both genetic and environmental (lifestyle) factors (Anderson et al., 2013, Asselbergs et al., 2012). In a meta-analysis of 32 genome-wide association studies (GWAS), many genes were proposed as candidate genetic factors, including peroxisome proliferator-activated receptor γ (PPAR-γ) (Asselbergs et al., 2012). In this study, PPAR-γ was associated with LDL-C and high-density lipoprotein-cholesterol (HDL-C). PPARs are ligand-activated nuclear hormone receptors and consist of three isotypes, PPAR-α, PPAR-β/δ, and PPAR-γ. PPAR-γ is highly expressed in adipose tissue and plays an important role in the regulation of adipocyte differentiation, lipogenesis, lipid storage, insulin sensitivity, glucose metabolism, and transcription of genes involved in these metabolic processes (Han et al., 2017). Meta-analyses of observational studies have shown that an rs1801282 polymorphism (PPAR-γ Pro12Ala) is associated with an increased risk of obesity and cardiovascular disease and a decreased risk of type 2 diabetes and diabetic nephropathy (Galbete et al., 2013, Li et al., 2015c, Gouda et al., 2010, Li et al., 2015b). Moreover, an rs3856806 polymorphism (PPAR-γ C161T) is associated with an increased risk of coronary artery disease and a decreased risk of myocardial infarction and acute coronary syndrome (Wang et al., 2015, Qian et al., 2016). Many natural and synthetic ligands influence the expression of PPAR-γ. The synthetic thiazolidinedione agonist, pioglitazone, which is an antidiabetic drug in clinical use, improves not only insulin sensitivity and glycemic control, but also plasma triglycerides, HDL-C, LDL particle concentration, and LDL particle size (Han et al., 2017, Schernthaner et al., 2013). Therefore, PPAR-γ polymorphisms are probably related to the risk of dyslipidemia.

To date, many epidemiological studies have examined associations between PPAR-γ polymorphisms and serum lipid levels (Li et al., 2015a). However, a number of issues remain unclear. First, few studies examined PPAR-γ single nucleotide polymorphisms (SNPs) other than rs1801282 and rs3856806 (Li et al., 2015a). Second, the sample sizes of these epidemiological studies were relatively small, and few had more than 1,000 participants (Tai et al., 2004). Third, few studies adjusted for potential confounding factors (e.g., demographic factors and lifestyle factors) (Tai et al., 2004, Moon et al., 2005, Yang et al., 2009, Gu et al., 2013, Gu et al., 2014a, Chehaibi et al., 2014, Gu et al., 2014b, Rooki et al., 2014, Fan et al., 2015). Fourth, many studies did not include community dwellers but patients with disease (Arashiro et al., 2003, Bhatt et al., 2013, Chao et al., 2004, Chehaibi et al., 2014, Chen et al., 2011, Dongxia et al., 2008, Evangelisti et al., 2009, Gu et al., 2013, Haseeb et al., 2009, Hui et al., 2008, Hung et al., 2012, Moon et al., 2005, Rooki et al., 2014, Tavares et al., 2005, Wan et al., 2010, Wang et al., 1999, Yang et al., 2009, Yilmaz-Aydogan et al., 2011, Zhou et al., 2012). Clarification of the roles of PPAR-γ polymorphisms in general populations is necessary to develop strategies for primary prevention.

We therefore aimed to elucidate the association of PPAR-γ polymorphisms, including rarely studied ones, with serum lipid levels in many community-dwelling adults while considering detailed information about their lifestyle.

Section snippets

Study design and participants

We conducted two cross-sectional studies using baseline and secondary survey data from the Shizuoka part of the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study (Hamajima and Group, 2007, Asai et al., 2009). Participants were recruited from health check examinees aged 35–69 years living in central and west parts of Shizuoka Prefecture. Among 13,740 examinees meeting eligibility criteria, 5,040 persons (37%) were enrolled from 2006 to 2007. Lifestyle and medical history including

Characteristics and genotypes of the participants

Of the 4,952 participants (3,356 men and 1,596 women), 2,114 (42.7%, 1,571 men and 543 women) had dyslipidemia and 1,431 (28.9%, 957 men and 474 women) had high LDL-C at the baseline survey. Of the 2,245 participants (1,550 men and 695 women), 933 (41.6%, 674 men and 259 women) had dyslipidemia and 716 (31.9%, 490 men and 226 women) had high LDL-C at the second survey. Table 1 compares characteristics between participants with dyslipidemia and those without at the baseline survey by sex. In

Discussion

In these two cross-sectional studies, we examined associations between PPAR-γ polymorphisms and serum lipids. In the baseline survey, minor allele homozygotes of rs3856806 and rs12497191 were associated with a lower risk of dyslipidemia, and minor allele homozygotes of rs3856806 were correlated with a lower risk of high LDL-C in all and male participants. Similar associations were found in the second survey.

Only a few studies have examined associations between PPAR-γ polymorphisms and

CRediT authorship contribution statement

Takashi Matsunaga: Conceptualization, Formal analysis, Writing - original draft. Mariko Naito: Data curation, Supervision. Guang Yin: Resources. Asahi Hishida: Data curation. Rieko Okada: Data curation. Sayo Kawai: Data curation. Tae Sasakabe: Data curation. Yuka Kadomatsu: Data curation. Mineko Tsukamoto: Data curation. Yoko Kubo: Data curation. Takashi Tamura: Data curation. Kenji Takeuchi: Data curation. Atsuyoshi Mori: Data curation. Nobuyuki Hamajima: Supervision, Project administration.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We greatly appreciate Dr. Yatami Asai and the staff of the Seirei Preventive Health Care Center for their support in conducting this study.

Financial support: This study was supported by Grants-in-Aid for Scientific Research for Special Priority Areas of Cancer (No. 17015018) and Innovative Areas (No. 22150001) and by JSPS KAKENHI Grants (Nos. 16H06277 and 15H02524) from the Japanese Ministry of Education, Culture, Sports, Science and Technology.

References (59)

  • R. Arashiro et al.

    Effect of Trp64Arg mutation of the beta3-adrenergic receptor gene and C161T substitution of the peroxisome proliferator activated receptor gamma gene on obesity in Japanese children

    Pediatr. Int.

    (2003)
  • Y. Asai et al.

    Baseline data of Shizuoka area in the Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study)

    Nagoya J. Med. Sci.

    (2009)
  • Y.S. Aulchenko et al.

    Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts

    Nat. Genet.

    (2009)
  • C. Baigent et al.

    Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

    Lancet

    (2010)
  • S.M. Boekholdt et al.

    Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis

    Circulation

    (2013)
  • A.L. Catapano et al.

    2016 ESC/EAS guidelines for the management of dyslipidaemias

    Eur. Heart J.

    (2016)
  • T.H. Chao et al.

    The 161TT genotype in the exon 6 of the peroxisome-proliferator-activated receptor gamma gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers

    Clin. Sci. (Lond).

    (2004)
  • D.I. Chasman et al.

    Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication

    Circ. Cardiovasc. Genet.

    (2008)
  • K. Chehaibi et al.

    Effect of the PPARγ C161T gene variant on serum lipids in ischemic stroke patients with and without type 2 diabetes mellitus

    J. Mol. Neurosci.

    (2014)
  • L. Dongxia et al.

    Association of peroxisome proliferator-activated receptor gamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome

    Circ. J.

    (2008)
  • W. Fan et al.

    Association and interaction of PPARα, δ, and γ gene polymorphisms with low-density lipoprotein-cholesterol in a Chinese Han population

    Genet. Test. Mol. Biomarkers

    (2015)
  • C. Galbete et al.

    Pro12Ala variant of the PPARG2 gene increases body mass index: an updated meta-analysis encompassing 49,092 subjects

    Obesity (Silver Spring)

    (2013)
  • GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause...
  • GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359...
  • H.N. Gouda et al.

    The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis

    Am. J. Epidemiol.

    (2010)
  • S.J. Gu et al.

    PPAR α and PPAR γ polymorphisms as risk factors for dyslipidemia in a Chinese Han population

    Lipids Health Dis.

    (2014)
  • S.J. Gu et al.

    Peroxisome proliferator-activated receptor γ polymorphisms as risk factors for dyslipidemia

    Mol. Med. Rep.

    (2014)
  • N. Hamajima et al.

    The Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study) to detect gene-environment interactions for cancer

    Asian Pac. J. Cancer Prev.

    (2007)
  • L. Han et al.

    PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ

    Future Cardiol.

    (2017)
  • Cited by (0)

    View full text